Publicaciones en las que colabora con Carlos Manuel Rodríguez Ortigosa (20)

2019

  1. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

    Hepatology, Vol. 69, Núm. 2, pp. 587-603

  2. Splicing events in the control of genome integrity: Role of SLU7 and truncated SRSF3 proteins

    Nucleic Acids Research, Vol. 47, Núm. 7, pp. 3450-3466

  3. The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis

    Hepatology, Vol. 69, Núm. 4, pp. 1632-1647

2018

  1. Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1326-1334

2017

  1. Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice

    Cell Death and Disease, Vol. 8, Núm. 10

  2. Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis

    Digestive Diseases, Vol. 35, Núm. 3, pp. 158-165

  3. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: Development of an FGF19-based chimeric molecule to promote fatty liver regeneration

    Gut, Vol. 66, Núm. 10, pp. 1818-1828

2014

  1. A GAPDH-mediated trans-nitrosylation pathway is required for feedback inhibition of bile salt synthesis in rat liver

    Gastroenterology, Vol. 147, Núm. 5, pp. 1084-1093

2013

  1. Zolmitriptan: A Novel Portal Hypotensive Agent Which Synergizes with Propranolol in Lowering Portal Pressure

    PLoS ONE, Vol. 8, Núm. 1

2012

  1. Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice

    Journal of Hepatology, Vol. 56, Núm. 2, pp. 367-373

2010

  1. Oral Methylthioadenosine Administration Attenuates Fibrosis and Chronic Liver Disease Progression in Mdr2-/- Mice

    PLoS ONE, Vol. 5, Núm. 12

2009

  1. The epidermal growth factor receptor ligand amphiregulin is a negative regulator of hepatic acute-phase gene expression

    Journal of Hepatology, Vol. 51, Núm. 6, pp. 1010-1020

2006

  1. Insulin-like growth factor 1 improves intestinal barrier function in cirrhotic rats

    Gut, Vol. 55, Núm. 9, pp. 1306-1312

2002

  1. Altered liver gene expression in CCl4-cirrhotic rats is partially normalized by insulin-like growth factor-I

    International Journal of Biochemistry and Cell Biology, Vol. 34, Núm. 3, pp. 242-252

  2. Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism rats

    Gut, Vol. 50, Núm. 5, pp. 701-706

1997

  1. Enhanced urinary excretion of cGMP in liver cirrhosis: Relationship to hemodynamic changes, neurohormonal activation, and urinary sodium excretion

    Digestive Diseases and Sciences, Vol. 42, Núm. 7, pp. 1416-1420

  2. S-adenosyl-L-methionine protects the liver against the cholestatic, cytotoxic, and vasoactive effects of leukotriene D4: A study with isolated and perfused rat liver

    Hepatology, Vol. 26, Núm. 2, pp. 330-335

1995

  1. Taurocholate-stimulated leukotriene C4 biosynthesis and leukotriene C4-stimulated choleresis in isolated rat liver

    Gastroenterology, Vol. 108, Núm. 6, pp. 1793-1801

1992

  1. Role of leukotrienes B4 and C4 in liver allograft rejection.

    Transplant international : official journal of the European Society for Organ Transplantation, Vol. 5 Suppl 1

1991

  1. Renal prostacyclin influences renal function in non-azotemic cirrhotic patients treated with furosemide

    Journal of Hepatology, Vol. 12, Núm. 2, pp. 170-175